학술논문

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Document Type
Article
Source
Nature Communications; 10/23/2023, Vol. 14 Issue 1, p1-12, 12p
Subject
CHRONIC lymphocytic leukemia
VENETOCLAX
CHLORAMBUCIL
TRANSCRIPTOMES
GENE expression
ALEMTUZUMAB
Language
ISSN
20411723
Abstract
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)